Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Survodutide.

Research draft

Survodutide is an investigational GLP-1 and glucagon receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Survodutide is an investigational GLP-1 and glucagon receptor agonist.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFOSynthetic peptide (dual agonist)
PRIMARY CONTEXTGLP-1 / glucagon dual agonist

Mechanism

It combines appetite and glucagon-related metabolic signalling.

Human research

Randomised obesity research includes a published late-stage trial; liver-disease evidence is a separate context.

Preclinical & other research

Metabolic models support its development rationale.

Safety & unknowns

Gastrointestinal burden and long-term outcomes require assessment in the studied population.

Regulatory status

Investigational in the reviewed sources; late-stage trial success is not marketing approval.

Reported use & evidence

Research profile draft

The supplied Survodutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds